Zhiguo Li

Conference Blood · November 3, 2025 AbstractIntroduction: Isocitrate dehydrogenase (IDH) mutations are observed in ~20% of patients with acute myeloid leukemia (AML). In the U ... Full text Cite

Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease

Conference Blood · November 3, 2025 AbstractBackground and Significance: Current therapies for steroid-refractory chronic graft versus host disease (SR-cGVHD) feature limited ... Full text Cite

Trial in Progress: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE ® Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia

Conference Blood · November 5, 2021 AbstractBackground: Relapsed Acute Lymphoblastic Leukemia (ALL) is not curable with standard therapies. Effective outpatient treatment, allowing patients to maintain a good quality of life, while offering a ... Full text Cite

Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant

Conference Blood · November 5, 2020 Allogeneic hematopoietic cell transplant (HCT) improves survival in patients with relapsed or high risk acute myeloid leukemia (AML). Complete remission (CR) is typically a pre-requisite for transplantation, though many do not achieve a formal CR. ... Full text Cite

Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

Conference Blood · November 13, 2019 Our group previously showed that B cells signal aberrantly through the B cell receptor (BCR) in allogeneic hematopoietic stem cell transplant (HCT) patients with active chronic graft-versus-host disease (cGVHD). Preclinical mouse studies have demon ... Full text Cite

Incidence of Invasive Fungal Infections in Acute Leukemia Patients Utilizing Micafungin Prophylaxis Compared to Second-Generation Azole Prophylaxis

Conference Blood · November 13, 2019 Introduction/Background:Standard therapy for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is myelosuppressive, and patients are expected to be neutropenic for a prolonged period. Due to t ... Full text Cite

The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2019 Link to item Cite

Expression and prognostic relevance of calcium calmodulin-dependent protein kinase kinase 2 (CaMKK2) in chronic lymphocytic leukemia (CLL).

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2019 Link to item Cite

Identifying Service Gaps from Public Patient Opinions Through Text Mining

Conference Communications in Computer and Information Science · January 1, 2018 Nowadays, healthcare systems have become increasingly patient-centered and the unstructured, open-ended and patient-driven feedback has drawn a significant attention from medical and healthcare organizations. Based on this, we are motivated to harness vari ... Full text Cite

Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.

Conference Journal of Clinical Oncology · May 20, 2017 8008 Background: The combination of bendamustine, pomalidomide, and dexamethasone (BPd) displays promising activity in heavily pretreated RRMM. In the Phase I portion, MTD was 120 mg/m2bendamustine/3mg pomali ... Full text Cite

Recipient-Derived BAFF and Alloantigen Synergistically Activate B Cells in Murine Chronic Gvhd

Conference Blood · December 2, 2016 AbstractIncreased B cell-activating factor (BAFF) and aberrant B cell survival and activation are associated with chronic graft versus host disease (cGVHD) in patients. Whether excessive BAFF production has ... Full text Cite

All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients

Conference Blood · December 2, 2016 AbstractAllogeneic hematopoietic stem cell transplantation (HCT)-related immune pathology severely limits patient (Pt) survival, largely due to infections. Chronic graft versus host disease (cGVHD) Pts are p ... Full text Cite

Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD)

Conference BLOOD · December 3, 2015 Link to item Cite

Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial

Conference Biology of Blood and Marrow Transplantation · February 2015 Full text Cite

Utilization of the NIH Consensus Guidelines Improves the Diagnostic Accuracy of Gastrointestinal Graft Versus Host Disease: A Five-Year Retrospective Study

Conference LABORATORY INVESTIGATION · February 1, 2015 Link to item Cite

Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation

Conference Biology of Blood and Marrow Transplantation · February 2015 Full text Cite

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Conference BLOOD · November 18, 2011 Link to item Cite

High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation

Conference BLOOD · November 18, 2011 Link to item Cite

Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies.

Conference BLOOD · November 19, 2010 Link to item Cite